Physician profile
Edward M Scheckowitz
NPI 1104877448
$9,728.69
in general payments reported to CMS, 2019-2025
45 companies · $896 in 2025
The $896 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,047 · 2020: $961 · 2021: $1,969 · 2022: $1,018 · 2023: $1,681 · 2024: $1,157 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,634 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,634.25 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,495.93 | 2019-2025 | Myrbetriq, Xtandi |
| Janssen Biotech, INC. | $1,314.00 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Abbvie INC. | $606.50 | 2019-2025 | Lupron Depot |
| Boston Scientific Corporation | $587.03 | 2019-2023 | Spaceoar Vue System - 10ml, Ams 700, Rezum Generator |
| Pfizer INC. | $577.87 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $491.77 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $486.22 | 2019-2024 | Provenge |
| Blue Earth Diagnostics | $430.23 | 2019-2024 | |
| Urogen Pharma, INC. | $355.53 | 2021-2025 | Jelmyto |
| Tolmar Pharmaceuticals, INC. | $344.33 | 2019-2022 | |
| Coloplast Corp | $254.56 | 2021-2025 | Speedicath |
| Sumitomo Pharma America, INC. | $251.18 | 2023-2025 | Orgovyx, Gemtesa |
| Laborie Medical Technologies Corp. | $246.70 | 2019-2025 | Optilume Bph Drug Coated Balloon Catheter, Endosheath Technology, Urgent PC Neuromodulation System |
| Tolmar, INC. | $215.54 | 2023-2025 | Jatenzo, Eligard |
| C. R. Bard, INC. & Subsidiaries | $172.43 | 2019-2023 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $163.62 | 2021-2023 | Axonics |
| Edap Technomed INC | $147.03 | 2024-2025 | |
| Amgen INC. | $145.44 | 2019-2021 | |
| Procept Biorobotics Corporation | $134.15 | 2023 | Aquabeam Robotic System |
| Rochester Medical Corporation | $126.18 | 2019-2021 | |
| Olympus America INC. | $116.08 | 2019-2025 | Itind System |
| Endo USA, INC. | $113.97 | 2024-2025 | Xiaflex |
| Antares Pharma, INC. | $87.48 | 2019-2024 | Xyosted |
| Myriad Genetic Laboratories, INC. | $86.18 | 2021-2025 | Prolaris |
| Accord Healthcare, INC. | $83.04 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $68.19 | 2021-2024 | Lynparza |
| Medtronic, INC. | $58.07 | 2024-2025 | Interstim, Altaviva |
| Becton, Dickinson and Company | $57.88 | 2023-2024 | Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire, Bard Urinary Drainage Bag |
| Karl Storz Endoscopy-America | $51.78 | 2019 | |
| Convatec INC. | $48.48 | 2019-2021 | |
| Calyxo, INC. | $46.12 | 2025 | Cvac Aspiration System |
| Myovant Sciences INC. | $44.86 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $40.00 | 2024-2025 | Adstiladrin |
| Ambu INC. | $33.00 | 2021-2024 | |
| Allergan, INC. | $31.34 | 2019-2020 | |
| Progenics Pharmaceuticals, INC. | $26.01 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.93 | 2022 | |
| 180 Medical, INC. | $24.89 | 2021 | |
| Metuchen Pharmaceuticals | $24.79 | 2021 | |
| Clarus Therapeutics INC. | $22.57 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.54 | 2023 | |
| Acerus Pharmaceuticals Corporation | $19.30 | 2022 | |
| Valencia Technologies Corporation | $17.83 | 2025 | Ecoin Device Kit |
| Halozyme INC | $17.55 | 2023 | |
| Telix Pharmaceuticals | $15.57 | 2025 | Illuccix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Scheckowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.